Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

1.

FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 Sep 1;20(17):4436-41. doi: 10.1158/1078-0432.CCR-14-0012. Epub 2014 May 30.

PMID:
24879797
[PubMed - in process]
2.

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS.

PLoS One. 2014 May 13;9(5):e96187. doi: 10.1371/journal.pone.0096187. eCollection 2014.

PMID:
24825167
[PubMed - in process]
Free PMC Article
3.

First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, Liu Q, Ringgold K, Pilaro AM, Tilley A, King KE, Graham L, Rellahan BL, Weinberg WC, Chi B, Thomas C, Hughes P, Ibrahim A, Justice R, Pazdur R.

Clin Cancer Res. 2013 Sep 15;19(18):4911-6. doi: 10.1158/1078-0432.CCR-13-1212. Epub 2013 Jun 25.

PMID:
23801166
[PubMed - indexed for MEDLINE]
Free Article
4.

Delineating Molecular Mechanisms of Squamous Tissue Homeostasis and Neoplasia: Focus on p63.

King KE, Ha L, Camilli T, Weinberg WC.

J Skin Cancer. 2013;2013:632028. doi: 10.1155/2013/632028. Epub 2013 Apr 22.

PMID:
23710361
[PubMed]
Free PMC Article
5.

Dysregulated ΔNp63α negatively regulates the maspin promoter in keratinocytes via blocking endogenous p73 binding.

King KE, Reddi DM, Ponnamperuma RM, Gerdes M, Weinberg WC.

Mol Carcinog. 2014 Sep;53(9):698-710. doi: 10.1002/mc.22022. Epub 2013 Mar 8.

PMID:
23475637
[PubMed - indexed for MEDLINE]
6.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group.

Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.

PMID:
23306000
[PubMed - indexed for MEDLINE]
7.

ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS; ARIES Study Team.

HIV Clin Trials. 2012 Sep-Oct;13(5):233-44. doi: 10.1310/hct1305-233.

PMID:
23134624
[PubMed - indexed for MEDLINE]
8.

TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer.

Lu H, Yang X, Duggal P, Allen CT, Yan B, Cohen J, Nottingham L, Romano RA, Sinha S, King KE, Weinberg WC, Chen Z, Van Waes C.

Cancer Res. 2011 Nov 1;71(21):6867-77. doi: 10.1158/0008-5472.CAN-11-2460. Epub 2011 Sep 20.

PMID:
21933882
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Dysregulated ΔNp63α inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes.

Ha L, Ponnamperuma RM, Jay S, Ricci MS, Weinberg WC.

PLoS One. 2011;6(7):e21877. doi: 10.1371/journal.pone.0021877. Epub 2011 Jul 15.

PMID:
21789189
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

HIV quality performance measures in a large integrated health care system.

Horberg M, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Kadlecik P, Remmers C, Dobrinich R, Quesenberry C, Silverberg M, Johnson M.

AIDS Patient Care STDS. 2011 Jan;25(1):21-8. doi: 10.1089/apc.2010.0315.

PMID:
21214376
[PubMed - indexed for MEDLINE]
11.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team.

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
[PubMed - indexed for MEDLINE]
12.

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES Study Team.

HIV Clin Trials. 2010 Mar-Apr;11(2):69-79. doi: 10.1310/hct1102-69.

PMID:
20542844
[PubMed - indexed for MEDLINE]
Free Article
13.

Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):407-17. doi: 10.1089/aid.2009.0189.

PMID:
20380480
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.

Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG.

Am J Hum Genet. 2010 Jan;86(1):88-92. doi: 10.1016/j.ajhg.2009.12.008. Epub 2009 Dec 31.

PMID:
20045101
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation.

Ponnamperuma RM, King KE, Elsir T, Glick AB, Wahl GM, Nister M, Weinberg WC.

J Pathol. 2009 Oct;219(2):263-74. doi: 10.1002/path.2600.

PMID:
19718706
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows.

Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS.

Am J Obstet Gynecol. 2009 Jul;201(1):116.e1-3. doi: 10.1016/j.ajog.2009.04.050.

PMID:
19576378
[PubMed - indexed for MEDLINE]
17.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866
[PubMed - indexed for MEDLINE]
18.

Learning disabilities do not go away: 20- to 25-year study of cognition, academic achievement, and affective illness.

Morris MA, Schraufnagel CD, Chudnow RS, Weinberg WA.

J Child Neurol. 2009 Mar;24(3):323-32. doi: 10.1177/0883073808324218.

PMID:
19258291
[PubMed - indexed for MEDLINE]
19.

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).

Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team.

HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x.

PMID:
19200175
[PubMed - indexed for MEDLINE]
20.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

PMID:
18832245
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk